Table 3.

Prevalence of ESBL- Ec sensitive to additional antibiotics for each country visited ^a

	All countries (n = 157)	India (n = 82)	Bhutan (n = 15)	Nepal (n = 41)	Sri Lanka (n = 19)
AMC	58.6	59.8	73.3	56.1	47.4
PIP-TAZ	96.8	95.1	100.0	95.1	100.0
CEP	35.0	46.3	26.7	24.4	15.8
MEM	100.0	100.0	100.0	100.0	100.0
SXT	51.0	48.8	73.3	51.2	42.1
CIP	59.2	47.6	86.7	70.7	63.2
NF	98.1	98.8	93.3	97.6	100.0
FOS	99.4	100.0	100.0	97.6	100.0
AMK	95.5	96.3	100.0	95.1	89.5
TOB	82.2	76.8	100.0	87.8	79.0
COL	100.0	100.0	100.0	100.0	100.0

Note: AMC, amoxicillin-clavulanate; PIP-TAZ, piperacillin-tazobactam; CEP, cefepime; MEM, meropenem; SXT, thrimetoprim-sulfamethoxazole; CIP, ciprofloxacin; NF, nitrofurantoin; FOS, fosfomycin; AMK, amikacin; TOB, tobramycin; COL, colistin.

^astated as %.